'); //--> Back to Boston.com homepage Arts | Entertainment Boston Globe Online Cars.com BostonWorks Real Estate Boston.com Sports digitalMass Travel

Top Ten
1. Charles River Labs
2. TJX
3. Perini
4. Investors Fin. Svcs.
5. Gillette
6. Staples
7. OneSource
8. Reebok
9. Bright Horizons
10. State Street
2002 Globe 100

Year's Best
Company of year
Highest market value
Highest sales
Comeback of the year
Biggest stock gain
Fastest growth

Overall performance
Bulls and Bears
  1. Clean Harbors
  2. Hologic
  3. NMT Medical
  4. DeWolfe
  5. Indevus Pharm.
  1. Sonus Networks
  2. Art Tech. Group
  3. Praecis Pharm.
  4. American Tower
  5. Dusa Pharmaceutical
Market value
Medical devices
  1. Cytyc
  2. Polymedica Corp.
  3. Perini
  4. Tweeter
  5. Boston Private Fin.
Company profiles
Globe 100 notes

Get the chart
The 2002 Globe 100
All the charts

Sections Boston Globe Online: Page One Nation | World Metro | Region Business Sports Living | Arts Editorials

Search the Globe:


The Boston Globe OnlineBoston.com The Best in Massachusetts Business
1.  C Y T Y C   C O R P .

Cytyc surges on success of Pap test

Grabs market lead after a slow start

    Globe 100
  1. Cytyc
  2. Polymedica Corp.
  3. Perini
  4. Tweeter
  5. Boston Private Financial

Get the chart
   The Growth 50
   Revenue growth
   All the charts

No Massachusetts company saw its sales and profits surge more in the past two years than Cytyc, a medical device company selling a new kind of Pap test to screen for cervical cancer.

The Boxborough company in 1996 began chipping away at the Pap smear -- a test that had reigned unrivaled for nearly 50 years and had spared thousands of women the ravages of cancer.

Progress came slowly at first. By the end of 1999, three years after the company's ThinPrep Pap test was approved by the Food and Drug Administration, Cytyc had gained only 19 percent of the market.

But 2000 was a bang-up year, followed by another successful year in 2001. The company now holds nearly 65 percent of the market. Sales grew an average of 65 percent a year over the past two years, and profits by an average of nearly 50 percent a year.

"The first 20 percent of the market is very difficult," said chief executive Patrick Sullivan. "From 20 to 80 percent market share, adoption tends to be quicker. Then, the final 20 percent becomes difficult again."

With the ThinPrep Pap test well on its way to dominating the market, Cytyc began looking for products to drive future growth. Last year, the company bought Pro-Duct Health for $167.5 million to gain a new technology to screen for breast cancer.

Known as ductal lavage, the technology is approved to screen women at risk for developing breast cancer or those with the disease. Sullivan said 5 million women nationwide fall into those categories, a market potentially worth $1.5 billion to $4 billion.

"It could be bigger than the Pap test, and it's an area where we believe we have the ability to make a real difference," Sullivan said.

The company hopes this quarter to complete its acquisition of another company, Digene. The $411 million merger, which would add tests for sexually transmitted diseases to the ThinPrep system, has been delayed by a federal antitrust review.


© Copyright 2002 Boston Globe Electronic Publishing Inc.
| Advertise | Contact us | Privacy policy |

Sponsors of the Globe 100 breakfast